Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Royalty Pharma plc
Royalty Pharma plc News
Royalty Pharma plc Quantitative Score
About Royalty Pharma plc
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Royalty Pharma plc Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Royalty Pharma plc Financials
Table Compare
Compare RPRX metrics with: | |||
|---|---|---|---|
Earnings & Growth | RPRX | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | RPRX | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | RPRX | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | RPRX | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Royalty Pharma plc Income
Royalty Pharma plc Balance Sheet
Royalty Pharma plc Cash Flow
Royalty Pharma plc Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Buy |
| Return on Equity | Buy |
| Return on Assets | Buy |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Sell |
| Price/Book Ratio | Neutral |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Royalty Pharma plc Dividends
| Yield (TTM) | Dividend (TTM) | |
|---|---|---|
Infinity% | 0.8700 |
| Payment Date | Dividend | Frequency |
|---|---|---|
| 2025-09-10 | 0.22 | Quarterly |
| 2025-06-10 | 0.22 | Quarterly |
| 2025-03-10 | 0.22 | Quarterly |
| 2024-12-10 | 0.21 | Quarterly |
| 2024-09-13 | 0.21 | Quarterly |
Historical Market Cap
Shares Outstanding
Royalty Pharma plc Executives
| Name | Role |
|---|---|
| Dr. James Folmar Reddoch Ph.D. | Executive Vice President of Investments & Chief Scientific Officer |
| Mr. Christopher Hite | Vice Chairman & Executive Vice President |
| Dr. Marshall Jonathan Urist M.D., Ph.D. | Executive Vice President of Research & Investments |
| Mr. Terrance P. Coyne | Executive Vice President & Chief Financial Officer |
| Mr. George Wingate Lloyd | Executive Vice President of Investments & Chief Legal Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. James Folmar Reddoch Ph.D. | Executive Vice President of Investments & Chief Scientific Officer | 1971 | 3.4M | |
| Mr. Christopher Hite | Vice Chairman & Executive Vice President | Male | 1968 | 1.26M |
| Dr. Marshall Jonathan Urist M.D., Ph.D. | Executive Vice President of Research & Investments | 1977 | 1.26M | |
| Mr. Terrance P. Coyne | Executive Vice President & Chief Financial Officer | Male | 1.26M | |
| Mr. George Wingate Lloyd | Executive Vice President of Investments & Chief Legal Officer | Male | 1960 | 1.26M |
Royalty Pharma plc Insider Trades
| Date | 8 Aug |
| Name | Norden Gregory |
| Role | Director |
| Transaction | Acquired |
| Type | C-Conversion |
| Shares | 144660 |
| Date | 11 Aug |
| Name | Norden Gregory |
| Role | Director |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 33500 |
| Date | 8 Aug |
| Name | Norden Gregory |
| Role | Director |
| Transaction | Disposed |
| Type | C-Conversion |
| Shares | 14466 |
| Date | 6 Aug |
| Name | Legorreta Pablo G. |
| Role | CEO, Chairman of the Board |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 21901 |
| Date | 8 Aug |
| Name | Legorreta Pablo G. |
| Role | CEO, Chairman of the Board |
| Transaction | Disposed |
| Type | G-Gift |
| Shares | 60000 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 8 Aug | Norden Gregory | Director | Acquired | C-Conversion | 144660 |
| 11 Aug | Norden Gregory | Director | Disposed | S-Sale | 33500 |
| 8 Aug | Norden Gregory | Director | Disposed | C-Conversion | 14466 |
| 6 Aug | Legorreta Pablo G. | CEO, Chairman of the Board | Acquired | A-Award | 21901 |
| 8 Aug | Legorreta Pablo G. | CEO, Chairman of the Board | Disposed | G-Gift | 60000 |